Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIVCo-infection

JAMA - Journal of the American Medical Association

Volumn 313, Issue 12, 2014, Pages 1232-1239

  Osinusi, Anu ^a,b,c   Townsend, Kerry ^b   Kohli, Anita ^d,e   Nelson, Amy ^a,b   Seamon, Cassie ^d   Meissner, Eric G ^b,f   Bon, Dimitra ^g   Silk, Rachel ^a,e   Gross, Chloe ^a,e   Price, Angie ^a,e   Sajadi, Mohammad ^a   Sidharthan, Sreetha ^d   Sims, Zayani ^d   Herrmann, Eva ^g   Hogan, John ^h   Teferi, Gebeyehu ^h   Talwani, Rohit ^a   Proschan, Michael ^b   Jenkins, Veronica ⁱ   Kleiner, David E ^j   Wood, Brad J ^d   Subramanian, G Mani ^c   Pang, Phillip S ^c   McHutchison, John G ^c   Polis, Michael A ^b   Fauci, Anthony S ^b   Masur, Henry ^d   Kottilil, Shyam ^a,b   more..

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GILEAD SCIENCES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g GOETHE UNIVERSITY   (Germany)

^h Unity Health Care Inc   (United States)

ⁱ Family Medical Counseling Services Inc   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CREATINE KINASE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTERFERON; INTERFERON LAMBDA 4; INTERLEUKIN 28B; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A; RALTEGRAVIR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR; URIDINE PHOSPHATE;

ABDOMINAL PAIN; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; IMMUNE RESPONSE; LIMIT OF QUANTITATION; MALE; MIXED INFECTION; MYALGIA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYALGIA; RNA, VIRAL; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 84925436650     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1373     Document Type: Article

References (26)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-1342.
2. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308(4):370-378.
3. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632-1641.
4. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
5. Chung RT, Andersen J, Volberding P, et al; AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-459.
6. Torriani FJ, Rodriguez-TorresM, Rockstroh JK, et al; APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-450.
7. Carrat F, Bani-Sadr F, Pol S, et al; ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839-2848.
8. Sulkowski M, Pol S, Mallolas J, et al; P05411 Study Investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597-605.
9. Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis. 2013;207(suppl 1):S26-S32.
10. Olysio (R) (simeprevir) [package insert]. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. 2013. Accessed December 2, 2014.
11. Solvadi (R) (sofosbuvir) [package insert]. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf. 2013. Accessed December 2, 2014.
12. Sulkowski MS, Naggie S, Lalezari J, et al; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353-361.
13. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial [published correction appears in JAMA. 2013;310(18):1987]. JAMA. 2013; 310(8):804-811.
14. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
15. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
16. Levey AS, Stevens LA, Schmid CH, et al CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
17. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0. National Institute of Allergy and Infectious Diseases website. http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. 2009. Accessed February 9, 2015.
18. Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164-171.
19. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
20. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431-435.
21. Guedj J, Neumann AU. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol. 2010;267(3):330-340.
22. Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat. 2010;17(12):825-833.
23. Ninomiya M, Ueno Y, Funayama R, et al. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol. 2012;50(3):857-866.
24. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis. 2014;59(11):1579-1587.
25. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-408.
26. Kowdley KV, Gordon SC, Reddy KR, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.